Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 531011

Next Previous
Drug Profile

S 531011

Alternative Names: S-531011

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 24 Jul 2026 M.D. Anderson Cancer Center plans a phase II trial for adenocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA in January 2027 (IV) (NCT07720115)
  • 21 May 2026 Shionogi plans the phase I/II IGNITE-CRC trial in Colorectal cancer (Combination therapy, Inoperable/unresectable, Metastatic disease) (IV), in May 2025 (NCT07591597)
  • 30 May 2025 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase-I/II aCCeleR8-001 trial in solid tumours presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top